A ferrocene-containing analogue of the MCU inhibitor Ru265 with increased cell permeability.

The mitochondrial calcium uniporter (MCU) is a transmembrane protein that mediates mitochondrial calcium (Ca) uptake. Inhibitors of the MCU are of interest for their applications as tools to study the role of Ca uptake on cellular function. In this study, we report two potent MCU inhibitors, Ru(μ-N)(NH)(FcCO) (, Fc = ferrocene, OTf = triflate) and Ru(μ-N)(NH)(PhCO) (). These compounds are analogues of the previously reported inhibitor Ru(μ-N)(NH)(Cl) (Ru265) that has been derivatized with ferrocenecarboxylate and benzoate ligands, respectively. Both compounds were synthesized and fully characterized by NMR spectroscopy, infrared spectroscopy, and X-ray crystallography. Under physiological conditions, and aquate with half-lives of 2.9 and 6.5 h, respectively, to produce Ru(μ-N)(NH)(HO) (Ru265') and the free carboxylates. Cyclic voltammetry of in ,'-dimethylformamide (DMF) reveals a prominent reversible 2e transfer event at 0.64 V vs SCE, corresponding to the simultaneous oxidation of both ferrocene-containing axial ligands. All three complexes also exhibit irreversible Ru-based reductions at potentials below -1 V vs SCE. DFT calculations of Ru265', , and confirm that the redox activity of arises from the ferrocene ligands. Furthermore, LUMO energies of the three compounds correlate with their irreversible reduction potentials. A systematic comparison on the biological properties of Ru265, , and was carried out. Both and inhibit Ca uptake in permeabilized HEK293T cells, but are 5-7 fold less potent than Ru265. In intact cells, is taken up by cells and inhibits the MCU to a similar extent as Ru265. , however, exhibits a 10-fold increase in cellular uptake over Ru265, which in turn also leads to a modest enhancement in MCU-inhibitory activity in intact cells. Moreover, in contrast to Ru265, is cytotoxic to HEK293T and HeLa cells with 50% growth inhibitory concentration values of 23.2 and 33.9 μM, respectively, a property that could be leveraged to develop MCU-targeting anticancer agents. These results establish as a potent MCU inhibitor and another example of how axial ligand functionalization of Ru265 can lead to new compounds within this class with diverse physical and biological properties.